Christophe Weber, CEO Takeda / Getty Images
September 26, 2019 07:16 AM EDT
R&D

Take­da turns to emerg­ing mar­kets, West­ern Eu­rope in scram­ble to of­fload Shire debt — re­port

Jason Mast

Editor

Weighed down by near­ly $50 bil­lion in debt since the Shire deal, Take­da is sell­ing off drugs in emerg­ing mar­kets and West­ern Eu­rope in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times